203 related articles for article (PubMed ID: 28123306)
1. RASSF1A promoter methylation is associated with increased risk of thyroid cancer: a meta-analysis.
Shou F; Xu F; Li G; Zhao Z; Mao Y; Yang F; Wang H; Guo H
Onco Targets Ther; 2017; 10():247-257. PubMed ID: 28123306
[TBL] [Abstract][Full Text] [Related]
2. Promoter methylation of p16 and RASSF1A genes may contribute to the risk of papillary thyroid cancer: A meta-analysis.
Jiang JL; Tian GL; Chen SJ; Xu LI; Wang HQ
Exp Ther Med; 2015 Oct; 10(4):1549-1555. PubMed ID: 26622524
[TBL] [Abstract][Full Text] [Related]
3. Associations of RASSF1A, RARβ, and CDH1 promoter hypermethylation with oral cancer risk: A PRISMA-compliant meta-analysis.
Wen G; Wang H; Zhong Z
Medicine (Baltimore); 2018 Mar; 97(11):e9971. PubMed ID: 29538221
[TBL] [Abstract][Full Text] [Related]
4. Associations between RASSF1A promoter methylation and NSCLC: a meta-analysis of published data.
Liu WJ; Tan XH; Guo BP; Ke Q; Sun J; Cen H
Asian Pac J Cancer Prev; 2013; 14(6):3719-24. PubMed ID: 23886171
[TBL] [Abstract][Full Text] [Related]
5. The relationship between RASSF1A gene promoter methylation and the susceptibility and prognosis of melanoma: A meta-analysis and bioinformatics.
Shao C; Dai W; Li H; Tang W; Jia S; Wu X; Luo Y
PLoS One; 2017; 12(2):e0171676. PubMed ID: 28207831
[TBL] [Abstract][Full Text] [Related]
6. The relationship between RASSF1A promoter methylation and thyroid carcinoma: A meta-analysis of 14 articles and a bioinformatics of 2 databases (PRISMA).
Niu H; Yang J; Yang K; Huang Y
Medicine (Baltimore); 2017 Nov; 96(46):e8630. PubMed ID: 29145283
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of promoter methylation in eight tumor-suppressor genes and its association with the risk of thyroid cancer.
Khatami F; Larijani B; Heshmat R; Keshtkar A; Mohammadamoli M; Teimoori-Toolabi L; Nasiri S; Tavangar SM
PLoS One; 2017; 12(9):e0184892. PubMed ID: 28926589
[TBL] [Abstract][Full Text] [Related]
8. Association of RASSF1A hypermethylation with risk of HBV/HCV-induced hepatocellular carcinoma: A meta-analysis.
Peng JL; Wu JZ; Li GJ; Wu JL; Xi YM; Li XQ; Wang L
Pathol Res Pract; 2020 Oct; 216(10):153099. PubMed ID: 32853942
[TBL] [Abstract][Full Text] [Related]
9. RASSF1A promoter methylation was associated with the development, progression and metastasis of cervical carcinoma: a meta-analysis with trial sequential analysis.
Zheng F; Yu H
Arch Gynecol Obstet; 2018 Feb; 297(2):467-477. PubMed ID: 29288321
[TBL] [Abstract][Full Text] [Related]
10. Aberrant promoter methylation of RASSF1A gene may be correlated with colorectal carcinogenesis: a meta-analysis.
Wang HL; Zhang Y; Liu P; Zhou PY
Mol Biol Rep; 2014 Jun; 41(6):3991-9. PubMed ID: 24566684
[TBL] [Abstract][Full Text] [Related]
11. Association of RASSF1A promoter methylation with lung cancer risk: a meta-analysis.
Huang YZ; Wu W; Wu K; Xu XN; Tang WR
Asian Pac J Cancer Prev; 2014; 15(23):10325-8. PubMed ID: 25556469
[TBL] [Abstract][Full Text] [Related]
12. [Meta-analysis of the Association between RASSF1A Gene Promoter Methylation and Non-small Cell Lung Cancer].
Wei H; Fang N; Guo L; Wu Z; Zhou Q
Zhongguo Fei Ai Za Zhi; 2015 Jul; 18(7):443-50. PubMed ID: 26182870
[TBL] [Abstract][Full Text] [Related]
13. Promoter methylation of the RASSF1A gene may contribute to colorectal cancer susceptibility: a meta-analysis of cohort studies.
Wang HL; Liu P; Zhou PY; Zhang Y
Ann Hum Genet; 2014 May; 78(3):208-16. PubMed ID: 24621386
[TBL] [Abstract][Full Text] [Related]
14. Association between Ras association domain family 1A promoter methylation and esophageal squamous cell carcinoma: a meta-analysis.
Yang JZ; Ji AF; Wang JS; Chen ZY; Wen SW
Asian Pac J Cancer Prev; 2014; 15(9):3921-5. PubMed ID: 24935575
[TBL] [Abstract][Full Text] [Related]
15. Aberrant Methylation of RASSF1A Closely Associated with HNSCC, a Meta-Analysis.
Meng RW; Li YC; Chen X; Huang YX; Shi H; Du DD; Niu X; Lu C; Lu MX
Sci Rep; 2016 Feb; 6():20756. PubMed ID: 26857374
[TBL] [Abstract][Full Text] [Related]
16. Salivary DNA Methylation as an Epigenetic Biomarker for Head and Neck Cancer. Part II: A Cancer Risk Meta-Analysis.
Rapado-González Ó; Martínez-Reglero C; Salgado-Barreira Á; Santos MA; López-López R; Díaz-Lagares Á; Suárez-Cunqueiro MM
J Pers Med; 2021 Jun; 11(7):. PubMed ID: 34206840
[TBL] [Abstract][Full Text] [Related]
17. Association between RASSF1A promoter methylation and renal cell cancer susceptibility: a meta-analysis.
Huang YQ; Guan H; Liu CH; Liu DC; Xu B; Jiang L; Lin ZX; Chen M
Genet Mol Res; 2016 Apr; 15(2):. PubMed ID: 27173228
[TBL] [Abstract][Full Text] [Related]
18. Role of RASSF1A promoter methylation in the pathogenesis of hepatocellular carcinoma: a meta-analysis of 21 cohort studies.
Li YS; Xie Q; Yang DY; Zheng Y
Mol Biol Rep; 2014 Jun; 41(6):3925-33. PubMed ID: 24566681
[TBL] [Abstract][Full Text] [Related]
19. Role of RASSF1A promoter methylation in the pathogenesis of ovarian cancer: a meta-analysis.
Si JG; Su YY; Han YH; Chen RH
Genet Test Mol Biomarkers; 2014 Jun; 18(6):394-402. PubMed ID: 24665911
[TBL] [Abstract][Full Text] [Related]
20. Association of RASSF1A promoter methylation with gastric cancer risk: a meta-analysis.
Shi DT; Han M; Gao N; Tian W; Chen W
Tumour Biol; 2014 Feb; 35(2):943-8. PubMed ID: 23982879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
